| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.01 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.02 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.14 | 0.02 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.02 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.074 | 0.02 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.12 | 0.03 |